NSCLC market set to grow to $12.7 billion in 2024, boosted by novel drugs

28 October 2015

The entry of 11 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.4 billion in 2014 to $12.7 billion in 2024, according to a new report from Decision Resources Group.

In addition to the recently approved programmed death-1 inhibitors Opdivo (nivolumab) from Bristol-Myers Squibb (NYSE: BMY) and Keytruda (pembrolizumab) from Merck & Co (NYSE: MRK), three more immune checkpoint inhibitors are slated to enter the NSCLC market: atezolizumab (Roche (ROG: SIX)/Genentech), durvalumab (AstraZeneca (LSE: AZN)/MedImmune) and avelumab (Merck KGaA (MRK: DE)/Pfizer (NYSE: PFE).

Growth drivers

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK